ALA-101 Treatment for CD19-Positive Blood Cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage study tests a new experimental therapy called ALA-101 for patients with certain types of lymphoma (a cancer of immune cells) or leukemia. The trial aims to see if this treatment is safe and effective for blood cancers that have a specific marker called CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with one of these specific blood cancers: non-Hodgkin lymphoma, diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphatic leukemia, or hairy cell leukemia
- Your liver and kidneys are working well enough for the treatment
- Your bone marrow is healthy enough to handle the treatment
- You expect to live at least 3 months
- You are willing to use birth control or avoid pregnancy for up to 12 months after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This trial tests a new cell therapy called QH101 for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to standard treatment. It aims to see if this therapy can help control the disease.
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Hear when a new Non Hodgkin Lymphoma (NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.